Chen, Y.J.Y.J.ChenTsai, T.H.T.H.TsaiLI-YING WANGHsieh, C.H.C.H.Hsieh2021-05-072021-05-0720171533-03461533-0338https://scholars.lib.ntu.edu.tw/handle/123456789/560380Concurrent chemoradiation therapy is the mainstay of treatment for many types of malignancies. However, concurrent chemoradiation therapy is associated with a greater number of systemic adverse effects than radiotherapy or chemotherapy alone.enRT-PK phenomenon; concurrent chemoradiation therapy; pharmacokinetics; radiotherapy; uncertainty[SDGs]SDG3anti programmed death 1 receptor antibody; cisplatin; fluorouracil; interleukin 16; interleukin 18; interleukin 2; interleukin 4; neutrophil collagenase; reactive nitrogen species; transforming growth factor beta1; tumor necrosis factor; unclassified drug; antineoplastic agent; cisplatin; neutrophil collagenase; area under the curve; biliary excretion; cancer chemotherapy; cancer palliative therapy; cancer radiotherapy; chemoradiotherapy; human; lymphatic system; radiosensitivity; Review; adverse drug reaction; genetics; multimodality cancer therapy; neoplasm; pathology; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Matrix Metalloproteinase 8; Neoplasmsreview10.1177/1533034617737011293324682-s2.0-85039414349http://www.scopus.com/inward/record.url?eid=2-s2.0-85039414349&partnerID=MN8TOARS42288940